Literature DB >> 18239127

Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis.

Masataka Asagiri1, Toshitake Hirai, Toshihiro Kunigami, Shunya Kamano, Hans-Jürgen Gober, Kazuo Okamoto, Keizo Nishikawa, Eicke Latz, Douglas T Golenbock, Kazuhiro Aoki, Keiichi Ohya, Yuuki Imai, Yasuyuki Morishita, Kohei Miyazono, Shigeaki Kato, Paul Saftig, Hiroshi Takayanagi.   

Abstract

Cathepsin K was originally identified as an osteoclast-specific lysosomal protease, the inhibitor of which has been considered might have therapeutic potential. We show that inhibition of cathepsin K could potently suppress autoimmune inflammation of the joints as well as osteoclastic bone resorption in autoimmune arthritis. Furthermore, cathepsin K-/- mice were resistant to experimental autoimmune encephalomyelitis. Pharmacological inhibition or targeted disruption of cathepsin K resulted in defective Toll-like receptor 9 signaling in dendritic cells in response to unmethylated CpG DNA, which in turn led to attenuated induction of T helper 17 cells, without affecting the antigen-presenting ability of dendritic cells. These results suggest that cathepsin K plays an important role in the immune system and may serve as a valid therapeutic target in autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18239127     DOI: 10.1126/science.1150110

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  119 in total

1.  Leukocyte cathepsin C deficiency attenuates atherosclerotic lesion progression by selective tuning of innate and adaptive immune responses.

Authors:  Veronica Herías; Erik A L Biessen; Cora Beckers; Dianne Delsing; Mengyang Liao; Mat J Daemen; Christine C T N Pham; Sylvia Heeneman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-11-13       Impact factor: 8.311

Review 2.  Protease signalling: the cutting edge.

Authors:  Boris Turk; Dušan Turk; Vito Turk
Journal:  EMBO J       Date:  2012-02-24       Impact factor: 11.598

Review 3.  The specialized roles of immature and mature dendritic cells in antigen cross-presentation.

Authors:  Richard A Hopkins; John E Connolly
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

Review 4.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2010-04-20       Impact factor: 25.606

Review 5.  Specialized roles for cysteine cathepsins in health and disease.

Authors:  Jochen Reiser; Brian Adair; Thomas Reinheckel
Journal:  J Clin Invest       Date:  2010-10-01       Impact factor: 14.808

Review 6.  Accessory molecules for Toll-like receptors and their function.

Authors:  Clarissa C Lee; Ana M Avalos; Hidde L Ploegh
Journal:  Nat Rev Immunol       Date:  2012-02-03       Impact factor: 53.106

7.  The silencing of cathepsin K used in gene therapy for periodontal disease reveals the role of cathepsin K in chronic infection and inflammation.

Authors:  W Chen; B Gao; L Hao; G Zhu; J Jules; M J MacDougall; J Wang; X Han; X Zhou; Y-P Li
Journal:  J Periodontal Res       Date:  2016-01-11       Impact factor: 4.419

8.  Odanacatib, A Cathepsin K-Specific Inhibitor, Inhibits Inflammation and Bone Loss Caused by Periodontal Diseases.

Authors:  Liang Hao; Jianwei Chen; Zheng Zhu; Michael S Reddy; John D Mountz; Wei Chen; Yi-Ping Li
Journal:  J Periodontol       Date:  2015-04-16       Impact factor: 6.993

9.  Genome-wide search for genes that modulate inflammatory arthritis caused by Ali18 mutation in mice.

Authors:  Koichiro Abe; Matthias Klaften; Akira Narita; Tetsuaki Kimura; Kenji Imai; Minoru Kimura; Isabel Rubio-Aliaga; Sibylle Wagner; Thilo Jakob; Martin Hrabé de Angelis
Journal:  Mamm Genome       Date:  2009-02-24       Impact factor: 2.957

10.  DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells.

Authors:  Johanna Tuomela; Jouko Sandholm; Mika Kaakinen; Ankita Patel; Joonas H Kauppila; Joanna Ilvesaro; Dongquan Chen; Kevin W Harris; David Graves; Katri S Selander
Journal:  Breast Cancer Res Treat       Date:  2013-11-10       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.